NovaBay (NBY) - Final Profit

Official company branding of novabay.com (NBY)

The net financial result of NovaBay Pharmaceuticals (NBY) demonstrates profit dynamics, where -0.01 represents the current metric level. NovaBay Pharmaceuticals (NBY) maintains its market position through patents for antimicrobial compositions and strict FDA certification. The Avenova brand sets the standard for eyelid hygiene, creating sustainable customer loyalty. The company is currently focusing on online sales, having temporarily suspended active research and development.

Net Income: novabay.com (NBY) for 07/04/2022 - 04/18/2026

Analytical breakdowns and data insights for company novabay.com (NBY)

- market value and analyst target forecast:
Stock Price NovaBay Pharmaceuticals, Inc.|NBY - Consensus Target
- market capitalization indicators:
Market Value NovaBay Pharmaceuticals|NBY - Enterprise Value
- business book valuation details:
Net Asset Value per Share NovaBay Pharmaceuticals|NBY - Company Net Assets|Market-to-Book Ratio novabay.com|NBY - Company Total Assets
- debt burden and liquidity indicators:
Debt to Capital NovaBay Pharmaceuticals|NBY - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient NovaBay Pharmaceuticals, Inc.|NBY - Company Debts|Debt to Book Value Ratio NovaBay Pharmaceuticals|NBY - Company Long-Term Debt|Short-Term Debt NovaBay Pharmaceuticals|Quick Liquidity novabay.com
- company profitability and valuation multiples indicators:
NBY - Net Profit
Basic company analysis:NovaBay
Signature product of NovaBay

The automation of sterile filling for ophthalmological solutions minimizes costs for NovaBay Pharmaceuticals (NBY), directly impacting bottom-line profitability. The company's current profit volume stands at -0.01, reflecting daily net income via a continuous data stream, which allows investors to assess the issuer's financial stability and promptly identify asset impairment risks during sharp fluctuations in the efficiency curve.

Main competitors

Alcon Corp (ALC) - Net Profit|Net Income BLCO|GKOS: Final Profit|Net Profit APLS|BLTE - Company Net Income|Ocular Therapeutix Corp - Net Income|Harrow Corp (HROW) - Company Net Income|Viridian Therapeutics - Net Profit|Company Net Income lenz-tx.com|Oculis AG (OCS) - Company Net Income|EYPT - Net Financial Result|Company Net Income Kodiak Pharma|Company Profit ALDX (Aldeyra)|Company Net Income KALA BIO, Inc. (KALA)|IRD - Company Net Income|OKYO Pharma - Net Income|Adverum Biotechnologies Inc. - Company Net Income|Outlook Pharma - Net Profit|CLSD - Net Profit|KPRX: Net Profit|ALIM (Alimera Sciences, Inc.) - Company Net Income|EYEN (Eyenovia Inc.) - Net Profit|Net Profit Guardion Health Sciences, Inc.|Net Income OCUP (Ocuphire)|OPT - Company Net Income